71 related articles for article (PubMed ID: 38569785)
1. An update on dietary therapies in paediatric Crohn's disease.
Gkikas K; Svolos V; White B; Gerasimidis K
Curr Opin Clin Nutr Metab Care; 2024 May; 27(3):304-312. PubMed ID: 38456807
[TBL] [Abstract][Full Text] [Related]
2. Exclusive enteral nutrition impacts peripheral blood mononuclear cell profile of children with Crohn's disease.
White B; Curle J; Gervais L; Wands D; Nichols B; Hansen R; Russell RK; Gerasimidis K; Milling S
J Pediatr Gastroenterol Nutr; 2024 May; ():. PubMed ID: 38779951
[TBL] [Abstract][Full Text] [Related]
3. Exclusive Enteral Nutrition Induces Remission in Pediatric Crohn's Disease via Modulation of the Gut Microbiota.
Gong D; Yu X; Wang L; Kong L; Gong X; Dong Q
Biomed Res Int; 2017; 2017():8102589. PubMed ID: 29124070
[TBL] [Abstract][Full Text] [Related]
4. Review article: Mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn's disease.
Melton SL; Taylor KM; Gibson PR; Halmos EP
Aliment Pharmacol Ther; 2023 May; 57(9):932-947. PubMed ID: 36894701
[TBL] [Abstract][Full Text] [Related]
5. Gut metabolome and microbiota signatures predict response to treatment with exclusive enteral nutrition in a prospective study in children with active Crohn's disease.
Nichols B; Briola A; Logan M; Havlik J; Mascellani A; Gkikas K; Milling S; Ijaz UZ; Quince C; Svolos V; Russell RK; Hansen R; Gerasimidis K
Am J Clin Nutr; 2024 Apr; 119(4):885-895. PubMed ID: 38569785
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition.
Svolos V; Hansen R; Nichols B; Quince C; Ijaz UZ; Papadopoulou RT; Edwards CA; Watson D; Alghamdi A; Brejnrod A; Ansalone C; Duncan H; Gervais L; Tayler R; Salmond J; Bolognini D; Klopfleisch R; Gaya DR; Milling S; Russell RK; Gerasimidis K
Gastroenterology; 2019 Apr; 156(5):1354-1367.e6. PubMed ID: 30550821
[TBL] [Abstract][Full Text] [Related]
7. Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn's disease.
Diederen K; Li JV; Donachie GE; de Meij TG; de Waart DR; Hakvoort TBM; Kindermann A; Wagner J; Auyeung V; Te Velde AA; Heinsbroek SEM; Benninga MA; Kinross J; Walker AW; de Jonge WJ; Seppen J
Sci Rep; 2020 Nov; 10(1):18879. PubMed ID: 33144591
[TBL] [Abstract][Full Text] [Related]
8. Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn's disease during enteral nutrition.
Gerasimidis K; Bertz M; Hanske L; Junick J; Biskou O; Aguilera M; Garrick V; Russell RK; Blaut M; McGrogan P; Edwards CA
Inflamm Bowel Dis; 2014 May; 20(5):861-71. PubMed ID: 24651582
[TBL] [Abstract][Full Text] [Related]
9. Fecal calprotectin is not a clinically useful marker for the prediction of the early nonresponse to exclusive enteral nutrition in pediatric patients with Crohn disease.
Copova I; Hradsky O; Zarubova K; Gonsorcikova L; Potuznikova K; Lerchova T; Nevoral J; Bronsky J
Eur J Pediatr; 2018 Nov; 177(11):1685-1693. PubMed ID: 30128744
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn's disease.
Zhou S; Huang Z; Hou W; Lin Y; Yu J
Inflamm Res; 2024 Feb; 73(2):199-209. PubMed ID: 38168701
[TBL] [Abstract][Full Text] [Related]
11. Unfermented β-fructan Fibers Fuel Inflammation in Select Inflammatory Bowel Disease Patients.
Armstrong HK; Bording-Jorgensen M; Santer DM; Zhang Z; Valcheva R; Rieger AM; Sung-Ho Kim J; Dijk SI; Mahmood R; Ogungbola O; Jovel J; Moreau F; Gorman H; Dickner R; Jerasi J; Mander IK; Lafleur D; Cheng C; Petrova A; Jeanson TL; Mason A; Sergi CM; Levine A; Chadee K; Armstrong D; Rauscher S; Bernstein CN; Carroll MW; Huynh HQ; Walter J; Madsen KL; Dieleman LA; Wine E
Gastroenterology; 2023 Feb; 164(2):228-240. PubMed ID: 36183751
[TBL] [Abstract][Full Text] [Related]
12. Dietary triggers of gut inflammation following exclusive enteral nutrition in children with Crohn's disease: a pilot study.
Gkikas K; Logan M; Nichols B; Ijaz UZ; Clark CM; Svolos V; Gervais L; Duncan H; Garrick V; Curtis L; Buchanan E; Cardigan T; Armstrong L; Delahunty C; Flynn DM; Barclay AR; Tayler R; Milling S; Hansen R; Russell RK; Gerasimidis K
BMC Gastroenterol; 2021 Dec; 21(1):454. PubMed ID: 34861829
[TBL] [Abstract][Full Text] [Related]
13. Microbiome and paediatric gut diseases.
Gerasimidis K; Gkikas K; Stewart C; Neelis E; Svolos V
Arch Dis Child; 2022 Sep; 107(9):784-789. PubMed ID: 34716173
[TBL] [Abstract][Full Text] [Related]
14. Diet and gut microbiota manipulation for the management of Crohn's disease and ulcerative colitis.
Svolos V; Gkikas K; Gerasimidis K
Proc Nutr Soc; 2021 Sep; ():1-15. PubMed ID: 34551834
[TBL] [Abstract][Full Text] [Related]
15. Stool metabolome-microbiota evaluation among children and adolescents with obesity, overweight, and normal-weight using 1H NMR and 16S rRNA gene profiling.
Jaimes JD; Slavíčková A; Hurych J; Cinek O; Nichols B; Vodolánová L; Černý K; Havlík J
PLoS One; 2021; 16(3):e0247378. PubMed ID: 33765008
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
